טוען...
Management of diabetes mellitus in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon
Canagliflozin is the first available oral inhibitor of sodium/glucose cotransporter 2 (SGLT2) in the market. At the outset it sounds excellent for the use in the elderly diabetic population, because of its minimal tendency to cause hypoglycemia. However, the clinician needs to exercise caution as it...
שמור ב:
| הוצא לאור ב: | J Pharmacol Pharmacother |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Medknow Publications & Media Pvt Ltd
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4231550/ https://ncbi.nlm.nih.gov/pubmed/25422561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0976-500X.142428 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|